Amended Statement of Ownership (sc 13g/a)

Date : 02/15/2020 @ 6:21AM
Source : Edgar (US Regulatory)
Stock : Orchard Therapeutics PLC (ORTX)
Quote : 12.89  2.22 (20.81%) @ 10:23PM
After Hours
Last Trade
Last $ 12.89 ◊ 0.00 (0.00%)

Amended Statement of Ownership (sc 13g/a)

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

 

ORCHARD THERAPEUTICS PLC
(Name of Issuer)

 

Ordinary Shares, par value £0.10 (represented by American Depositary Shares)
(Title of Class of Securities)

 

68570P101
(CUSIP Number)

 

December 31, 2019
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  x Rule 13d-1(b)

 

  ¨ Rule 13d-1(c)

 

  ¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 68570P101 13G

 

  1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

 

RA Capital Management, L.P.

 

  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨ 
    (b) ¨ 

 

  3. SEC Use Only

 

  4. Citizenship or Place of Organization Delaware

 

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 0 shares
 
6. Shared Voting Power 6,389,901 shares
 
7. Sole Dispositive Power 0 shares
 
8. Shared Dispositive Power 6,389,901 shares

 

  9.

Aggregate Amount Beneficially Owned by Each Reporting Person

6,389,901 shares

 

  10.

Check if the Aggregate Amount in Row (9) Excludes

Certain Shares (See Instructions)

¨

 

  11.

Percent of Class Represented by Amount in Row (9)

6.6%1

 

  12.

Type of Reporting Person (See Instructions)

IA, PN

 

 

 

1 The reporting person is the beneficial owner of 6,389,901 of the Issuer’s American Depository Shares (“ADSs”) representing 6,389,901 of the Issuer’s ordinary shares, which constitute approximately 6.6% of the Issuer’s outstanding ordinary shares. The percentage calculation assumes that there are currently 96,517,534 outstanding ordinary shares of the Issuer, based on the Issuer’s Form F-3 as filed with the Securities and Exchange Commission (“SEC”) on November 1, 2019.

 

 

 

 

CUSIP No. 68570P101 13G

 

  1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

 

Peter Kolchinsky

 

  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨ 
    (b) ¨ 

 

  3. SEC Use Only

 

  4. Citizenship or Place of Organization

United States

 

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 0 shares
 
6. Shared Voting Power 6,389,901 shares
 
7. Sole Dispositive Power 0 shares
 
8. Shared Dispositive Power 6,389,901 shares

 

  9.

Aggregate Amount Beneficially Owned by Each Reporting Person

6,389,901 shares

 

  10.

Check if the Aggregate Amount in Row (9) Excludes

Certain Shares (See Instructions)

¨

 

  11.

Percent of Class Represented by Amount in Row (9)

6.6%1

 

  12.

Type of Reporting Person (See Instructions)

HC, IN

 

 

 

1 The reporting person is the beneficial owner of 6,389,901 of the Issuer’s American Depository Shares (“ADSs”) representing 6,389,901 of the Issuer’s ordinary shares, which constitute approximately 6.6% of the Issuer’s outstanding ordinary shares. The percentage calculation assumes that there are currently 96,517,534 outstanding ordinary shares of the Issuer, based on the Issuer’s Form F-3 as filed with the Securities and Exchange Commission (“SEC”) on November 1, 2019.

 

 

 

 

CUSIP No. 68570P101 13G

 

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

 

Rajeev Shah

 
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)       ¨

(b)       ¨

 
SEC Use Only
 
Citizenship or Place of Organization United States

 

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5.

Sole Voting Power  

0 shares

6. Shared Voting Power 6,389,901 shares
7. Sole Dispositive Power 0 shares
8. Shared Dispositive Power 6,389,901 shares

 

Aggregate Amount Beneficially Owned by Each Reporting Person

6,389,901 shares

 

Check if the Aggregate Amount in Row (9) Excludes

Certain Shares (See Instructions)

¨

 

 

Percent of Class Represented by Amount in Row (9)

6.6%1

 

Type of Reporting Person (See Instructions)

HC, IN

 

 

 

1The reporting person is the beneficial owner of 6,389,901 of the Issuer’s American Depository Shares (“ADSs”) representing 6,389,901 of the Issuer’s ordinary shares, which constitute approximately 6.6% of the Issuer’s outstanding ordinary shares. The percentage calculation assumes that there are currently 96,517,534 outstanding ordinary shares of the Issuer, based on the Issuer’s Form F-3 as filed with the Securities and Exchange Commission (“SEC”) on November 1, 2019.

 

 

 

 

CUSIP No. 68570P101 13G

 

Item 1.

(a) Name of Issuer: Orchard Therapeutics PLC (the “Issuer”).

 

(b) Address of the Issuer’s Principal Executive Offices: 108 Cannon Street, London EC4N 6EU United Kingdom.

 

Item 2.

 

(a) Name of Person Filing: This Amendment No. 1 to Schedule 13G amends and restates the Statement on Schedule 13G filed by RA Capital Management, L.P. (“RA Capital”), Peter Kolchinsky, and Rajeev Shah (collectively, the “Reporting Persons”) on February 14, 2019.

 

The Common Stock reported herein includes 5,802,586 shares held by RA Capital Healthcare Fund, L.P. (the “Fund”) and 587,315 shares held in a separately managed account (the “Account”). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund and the Account. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

 

(b) Address of Principal Business Office: The principal business office of the Reporting Persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116.

 

(c) Citizenship: RA Capital is a Delaware limited partnership. Dr. Kolchinsky and Mr. Shah are United States citizens.

 

(d) Title and Class of Securities: American Depositary Shares (“ADSs”) of the Issuer.

 

(e) CUSIP Number: 68570P101

 

 

 

 

CUSIP No. 68570P101 13G

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(e) RA Capital Management, L.P. is a registered investment adviser and is filing this statement in accordance with §240.13d-1(b)(1)(ii)(E);

 

(g) Peter Kolchinsky and Rajeev Shah are control persons and are filing this statement in accordance with §240.13d-1(b)(1)(ii)(G).

 

Item 4. Ownership:

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover page(s).

   
(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

 
(c) Number of shares as to which such person has:
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

     
  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

     
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

     
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

 

Item 5. Ownership of Five Percent or Less of a Class:

 

Not applicable.

 

 

 

 

CUSIP No. 68570P101 13G

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group:

 

Not applicable.

 

Item 9. Notice of Dissolution of Group:

 

Not applicable.

 

Item 10. Certification:

 

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Exhibits

 

1 Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2019.

 

 

 

 

CUSIP No. 68570P101 13G

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Date: February 14, 2020
   
   
  RA CAPITAL MANAGEMENT, L.P.
   
  By: /s/ Peter Kolchinsky
  Peter Kolchinsky
  Authorized Signatory
   
  PETER KOLCHINSKY
   
  /s/ Peter Kolchinsky
   
  RAJEEV SHAH
   
  /s/ Rajeev Shah

 

 

 

Orchard Therapeutics (NASDAQ:ORTX)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Orchard Therapeutics Charts.

Orchard Therapeutics (NASDAQ:ORTX)
Intraday Stock Chart

Today : Friday 28 February 2020

Click Here for more Orchard Therapeutics Charts.

Latest ORTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.